Human proBNP, BNP and NT-proBNP

Brain natriuretic peptide (BNP) and the N-terminal part of the BNP precursor proBNP (NT-proBNP) are established diagnostic and prognostic biomarkers of heart failure (HF). HF is a severe clinical and public health problem that is characterized by an increasing prevalence and economic cost. According to the American Heart Association, its prevalence extends to 6.5 million people in the United States with nearly 1 million new cases being reported each year (1); on a global level, the prevalence reaches more than 23 million people. Chronic heart disease, hypertension and diabetes are among the known risk factors and the prevalence of HF is also higher for those people aged over 65 years. HF is associated with significant morbidity and mortality.

BNP, NT-proBNP and proBNP as diagnostic markers

Clinical guidelines recommend measuring either BNP or NT-proBNP in order to rule out HF in the initial assessment of a patient with suspected acute heart failure. Both markers can also be used to monitor the progression of the disease. The clinical values of BNP and NT-proBNP are similar (2-3) and both markers are currently used in clinical practice.

In healthy adults, the upper limit of BNP in plasma is 35 pg/ml and that of NT-proBNP is 125 pg/ml (4). However, the values depend on age and gender, and are higher in elderly people and women.

The concentrations of the analytes correlate with the severity of the disease and can increase by up to several hundred-fold. It has been reported that both peptide concentrations are already elevated in asymptomatic patients during the very early stage of heart failure (NYHA I stage according to the New York Heart Association classification). NYHA classes II and III, and especially class IV patients, demonstrate significantly elevated concentrations of BNP and NT-proBNP in their blood. Therefore, peptide measurements in human blood are widely used for the evaluation of patients with suspected HF and when assessing the severity of the disease.

Determining BNP or NT-proBNP concentration is also useful for the risk stratification of the patients with different cardiac pathologies. Patients who will develop complications in the future are characterized by significantly higher BNP and NT-proBNP concentrations than those patients without complications. In patients with congestive HF, high BNP or NT-proBNP levels predict death and are relevant to cardiovascular risk. Meanwhile, in patients with acute coronary syndrome, elevated levels of both peptides are predictive for mortality and severe HF.

In addition to NT-proBNP and BNP, their precursor proBNP1-108 is also found in significant amounts in the blood samples derived from HF patients. Assays detecting only proBNP might have an enhanced analytical specificity.
Biochemistry of proBNP and its derivatives

The gene encoding for BNP is activated in cardiomyocytes in response to myocardial stretch due to pressure or volume overload. This results in the synthesis of a 134 amino acid residues (a.a.r.) long intracellular precursor prepropeptide preproBNP. Following the removal of the signal peptide, further processing of the propeptide results in the release of the biologically active BNP (32 a.a.r.) and NT-proBNP (76 a.a.r.) which has no known biological activity. Both BNP and NT-proBNP as well as unprocessed proBNP are secreted into the bloodstream and circulate in human blood (see Figure 1). BNP is efficiently cleared from the circulation and its half-life is approximately 20 minutes. The half-life of NT-proBNP is longer – 60-120 minutes – which explains the apparently higher concentration of NT-proBNP vs. BNP in blood.

ProBNP is an O-glycosylated protein with seven identified glycosylation sites (5). All of the glycosylation sites are located on the NT-proBNP part whereas BNP is not glycosylated. We have previously shown that the glycosylation status of one amino acid, T71, is crucial to the processing of proBNP into BNP and NT-proBNP. T71 is located close to the cleavage site and the convertase-dependent cleavage can only occur if T71 is not glycosylated. Consequently, the majority of the unprocessed proBNP found in circulation has an O-glycan on T71 whereas the same amino acid in NT-proBNP is not glycosylated (6).

Reagents for immunoassay development

At HyTest, we have been studying proBNP and its derivatives for several years. To this end, we have published ten articles in peer reviewed journals (for further details, see pp. 14-15). We provide a broad range of well characterized monoclonal antibodies (MAbs) that allow for the development of sensitive and reliable immunoassays that are suitable for the detection of proBNP, NT-proBNP and BNP in clinical samples.

We also provide different recombinant antigens that can be used as standards and calibrators in immunoassays.

Figure 1. Scheme of proBNP processing. ProBNP is formed following the translation and cleavage of the signal peptide of preproBNP molecule. It is then glycosylated at several sites. Two pools of proBNP that are different in the status of T71 glycosylation are formed: non-glycosylated at T71 and molecules glycosylated at this site. Glycosylation suppresses the subsequent processing of proBNP. Only proBNP that is not glycosylated at T71 can be effectively processed into BNP and NT-proBNP. Non-processed proBNP, NT-proBNP and BNP are released into the blood.
**BNP assay development**

Human BNP is a 3.5 kDa peptide that is formed by the cleaving of proBNP into NT-proBNP (the N-terminal part) and BNP (the C-terminal part). BNP consists of the amino acids 77-108 of proBNP. However, in the BNP molecule, the amino acids are usually numbered as 1-32. The calculated pI of BNP is 10.95.

BNP is a peptide hormone with natriuretic, vasodilatory and renin inhibitory properties (7-9). It belongs to a family of structurally similar peptide hormones that also includes atrial natriuretic peptide (ANP), C-type natriuretic peptide (CNP) and urodilatin. These peptides are characterized by a 17 amino acid ring structure that is formed by a disulfide bond between two cysteine residues. The ring structure is highly homologous between the different natriuretic peptides with 11 out of 17 amino acid residues being identical among the peptides. In human BNP, the disulfide bond is between C10 and C26 (see Figure 2).

**BNP is an unstable molecule**

BNP is known to be an unstable molecule (10-11). Several studies have revealed that BNP is presented by multiple forms in the plasma from HF patients, being truncated from both N- and C-termini. Only a small portion of BNP circulates as a full-size BNPI-32 molecule (12). Proteases such as dipeptidyl peptidase IV (DPP IV) and neutral endopeptidase (neprilysin, NEP) have been reported to degrade BNP, which gives rise to BNP3-32 and BNP5-32, respectively (13-14). Some studies have suggested that insulin-degrading enzyme (IDE) can also degrade BNP into smaller peptides (15-16). The known sites of BNP proteolytic degradation are summarized in Figure 2.

**BNP immunoreactive forms in human blood**

As the cleavage of proBNP into NT-proBNP and BNP is only partial and depends on the posttranslational glycosylation of the protein, both BNP and proBNP are released into circulation. Both of these forms can be recognized by antibodies that are specific to the BNP molecule unless the epitopes are destroyed through truncation by proteases.

We analyzed plasma samples from HF patients by using gel filtration and measuring the BNP immunoreactivity of the fractions through the use of a highly sensitive antibody pair 50E1-24C5 which is able to detect different BNP forms with equal specificity. The results of the gel filtration studies showed that the BNP assay detected two peaks with BNP immunoreactivity in all samples. The first peak represents the proBNP form while the second, smaller peak, represents the BNP form (see Figure 3). We have previously shown that the predominant BNP immunoreactive form in human blood is the unprocessed proBNP (17).

**Figure 2. Schematic representation of human BNP and the main sites of its proteolytic degradation by different proteases.** DPP IV is dipeptidyl peptidase IV, NEP is neutral endopeptidase (neprilysin), IDE is insulin-degrading enzyme.

**Figure 3. Gel filtration studies of endogenous proBNP and BNP.** Proteins from one representative plasma sample of a HF patient were separated on the Superdex Peptide column (GE Healthcare). BNP immunoreactivity in fractions was measured by the 50E1-24C5 assay. The first peak corresponds to proBNP, while the second peak corresponds to the BNP form.
Conventional BNP sandwich immunoassays

We provide several MAb s that are specific to different epitopes on the BNP molecule (see Figure 4). Several different MAb combinations allow for the development of highly specific, sensitive and rapidventional-type sandwich immunoassays that are suitable for the quantitative measurement of BNP and proBNP in human blood. Table 1 shows the recommended antibody pair combinations for conventional sandwich immunoassays.

All of the recommended capture-detection pairs detect both the BNP peptide and the unprocessed proBNP protein with the same efficiency (see Figure 5 below). However, it is important to note that the cross-reactivity of commercial BNP assays to proBNP varies (18-20). All of the recommended combinations have been tested with the plasma samples of HF patients. As antibodies might display a varying performance on different assay platforms, we recommend trying at least four or five two-site MAb combinations when developing an immunoassay. This will ensure that a pair is selected which will perform optimally in the given assay conditions and platform.

As a standard for BNP immunoassays we recommend using the recombinant glycosylated proBNP (Cat. # 8GBP3, see p. 11) as the BNP-immunoreactivity in blood is predominantly represented by the glycosylated proBNP.

**Calibration curves.** All of the recommended BNP immunoassays recognize three BNP-comprising polypeptides with the same efficiency: synthetic BNP, recombinant non-glycosylated proBNP and recombinant glycosylated proBNP. Representative calibration curves for two sandwich fluoroimmunoassays 50E1-24C5 (A) and 57H3-429 (B) are presented in Figure 5. We have previously published a detailed description of the 50E1-24C5 immunoassay and shown that its analytical sensitivity (with synthetic BNP used as a calibrator) in our in-house assay is better than 0.5 pg/ml (17). Other antibody pairs that are listed above also recognize BNP with extremely high sensitivity.

![Figure 4. Epitope mapping of anti-BNP antibodies.](image)

![Table 1. Recommended MAb pairs for conventional BNP sandwich immunoassays.](table)

**Table 1. Recommended MAb pairs for conventional BNP sandwich immunoassays.**

Data is based on the results obtained using our in-house time-resolved fluorescence immunoassay platform.

![Figure 5. Calibration curves for 50E1 – 24C5 (A) and 57H3-429 (B) sandwich fluoroimmunoassays with three peptides that contain a BNP1-32 motif.](chart)

The antigens used were synthetic BNP (Bachem), recombinant non-glycosylated proBNP and recombinant glycosylated proBNP. A mixture of antibodies (50 μl) and antigen (50 μl) was incubated for 30 minutes at room temperature in streptavidin-coated plates.
**HyTest’s BNP assays show good correlation with commercially available assays.** BNP concentration was measured in 40 EDTA-plasma samples that were obtained from HF patients using two different in-house assays and two different commercial assays that utilize similar epitopes. In Figure 6 (A), we compared our 57H3-429 assay utilizing antibodies that were specific to epitopes 26-32 and 5-13 respectively to the Abbott iSTAT® BNP assay that utilizes antibodies with identical epitope specificities. The results of the measurements obtained with the BNP assay 57H3-429 correlated well with the results of measurements obtained with the Abbott iSTAT BNP assay ($R^2=0.99$).

In Figure 6 (B), we compared our 50E1-130 assay (antibodies specific to epitopes 26-32 and 15-22 respectively) to the Siemens BNP assay that utilizes antibodies specific to epitopes 27-32 and 14-21. Our prototype assay 50E1-130 showed good correlation with the Siemens BNP assay ($R^2=0.97$).

Each assay was calibrated with internal standard material. The epitope specificities of the commercial assays are provided on the IFCC website www.ifcc.org.

**Single Epitope Sandwich BNP Assay (SES-BNP™)**

We have developed a unique type of immunoassay for BNP. In this Single Epitope Sandwich BNP (SES-BNP™) assay only the capture antibody recognizes BNP. The detection antibody is specific to the complex of capture antibody and BNP, and it does not recognize these two molecules in their free forms (see Figure 7).

Since BNP is presented by multiple truncated forms in the plasma of HF patients and only a small portion as the full size molecule, it is likely that BNP assays utilizing MAbs specific to the very terminal epitopes (especially C-terminal) would be able to underestimate the real BNP concentration in the sample. The SES-BNP assay utilizes only one relatively stable epitope 11-17 on the ring structure and therefore the assay improves the precision and sensitivity of BNP measurements, and also demonstrates a higher apparent stability of the BNP antigen in the sample.

**Prototype SES-BNP assay.** HyTest’s prototype SES-BNP assay is a one-step assay that uses the biotinylated capture MAb 24C5 and the detection MAb Ab-BNP2 which is labeled with a stable Eu³⁺ chelate. Both MAbs and the antigen are simultaneously incubated in streptavidin-coated wells for 30 minutes and this is followed by a wash step and addition of the enhancement solution, and immediately measured using our in-house Delfia immunoassay platform. The limit of detection of the SES-BNP assay is 0.4 pg/ml (human synthetic BNP, Peptide Institute, Japan). This is the highest sensitivity described in literature for all commercial and experimental BNP assays. A detailed description of the prototype SES-BNP assay has been published (21).

As a standard for the SES-BNP immunoassay we recommend using the recombinant glycosylated proBNP (Cat.# 8GBP3, see p. 11) as the BNP-immunoreactivity in blood is predominantly represented by the glycosylated proBNP.
**Equal detection of BNP and proBNP.** In order to precisely measure the BNP immunoreactivity in a sample, the assay antibodies should recognize both BNP and proBNP with the same efficiency. We tested this by assessing the immunoreactivity of three different forms containing the BNP motif: synthetic BNP, recombinant non-glycosylated proBNP and recombinant glycosylated proBNP. Figure 8 shows that the SES-BNP assay was able to recognize all three molecules with the same efficiency.

**Apparent improved stability of BNP.** The apparent stability of BNP at room temperature was compared between the SES-BNP assay and a conventional sandwich immunoassay where the antibodies recognize distantly located epitopes (50E1-24C5). Figure 9 shows that for both the synthetic BNP and endogenous BNP, the immunoreactivity of the antigen decreased more quickly when it was measured with the conventional sandwich immunoassay. This phenomenon was more pronounced with the synthetic BNP.

**Figure 8.** Recognition of different antigen forms displaying BNP-immunoreactivity by the SES-BNP assay. Calibration curves for synthetic BNP, recombinant non-glycosylated proBNP and recombinant glycosylated proBNP.

**Figure 9.** Stability studies of BNP. Synthetic BNP (Bachem, Japan) reconstituted in individual normal human EDTA-plasma (A) and two individual HF patient EDTA-plasma samples (B) were incubated at room temperature (24°C) for different time periods and measured using the SES-BNP assay (blue) and a conventional type sandwich BNP assay 50E1-24C5 (red). Results of the HF patient samples (B) are presented as mean ±SD.
The SES-BNP assay correlates well with the Beckman Coulter Access® 2 BNP assay. BNP was measured in 40 EDTA-plasma samples from HF patients with the SES-BNP assay and a commercially available conventional type BNP immunoassay from Beckman Coulter. In the Beckman assay, only the epitope specificity of the detection antibody (5-13 a.a.r.) is known. Both assays were calibrated with internal standard materials. The correlation between the results of the measurements was high ($R^2 = 0.97$) and it may be that the Beckman Coulter Access 2 assay also utilizes antibodies that are specific to the relatively stable parts of the BNP molecule (see Figure 10).

![Graph showing correlation between SES-BNP and Beckman Access 2 BNP assays]

**Figure 10.** HyTest’s SES-BNP prototype assay shows good correlation with the Beckman Coulter Access 2 BNP assay.

Inhibition of neprilysin and its effect on BNP immunoassays

The augmentation of the endogenous BNP through preventing its breakdown by a neprilysin inhibitor is considered to be a potential therapeutic strategy in HF. Recently, a new HF drug named Entresto™ (Novartis) was approved by the Food and Drug Administration. One of the active components in this drug is a neprilysin inhibitor and it has been suggested that treatment with this drug might have an impact on the level of BNP-related peptides.

The majority of commercially available BNP assays are designed as sandwich-type immunoassays that utilize two MAbs which are specific to distantly located epitopes. At least one of these two antibodies is specific to the ring structure while the other one is usually specific to the C-terminus of the BNP molecule. As one of the neprilysin cleavage sites is located in the BNP ring structure (R17-I18; see Figure 2), it would be reasonable to suggest that immunoassays utilizing antibodies with epitopes comprising the neprilysin cleavage site would be sensitive to the proteolytic activity of neprilysin. However, the complexity of the biochemistry of the natriuretic peptides as well as the diversity of the different forms of heart failure mean that there is no straightforward answer to this question.

We have investigated the effect of neprilysin activity on various BNP immunoassays by studying the sensitivity of BNP and proBNP to neprilysin. According to our studies, it appears that although the BNP-32 molecule was susceptible to the cleavage of neprilysin, the SES-BNP assay was resistant to the effect of neprilysin. This was likely due to the fact that the epitope which the capture antibody recognizes lies outside the neprilysin cleavage site. In comparison, an immunoassay with one of the antibodies specific to the epitope 14-21 containing the neprilysin cleavage site was sensitive to neprilysin as expected (22). In addition to the SES-BNP assay, the 57H3-429 pair is also resistant to the effect of neprilysin (data not shown).

We have also shown that the unprocessed proBNP, which is the main BNP immunoreactive form in blood, is actually not cleaved by neprilysin and therefore assays designed to only recognize proBNP should not be affected by drugs such as Entresto™ (22).
**NT-proBNP assay development**

NT-proBNP is the N-terminal portion of proBNP that consists of 76 amino acids and seven O-glycosylation sites. No biological activity has been found for NT-proBNP. Its half-life is 3-6 times longer than that of BNP, which means it is a somewhat more stable marker in clinical samples. The clinical value of NT-proBNP is similar to BNP. The calculated pI of NT-proBNP is 8.45 and molecular weight is 8.5 kDa. However, due to glycosylation its apparent molecular weight is higher (17).

**Glycosylation influences the detection of NT-proBNP**

Our studies have revealed that the glycosylation of NT-proBNP negatively affects its recognition by some antibodies. The central part of the NT-proBNP molecule (a.a.r. 28-56) is scarcely accessible for antibodies due to O-glycosylation, whereas regions 13-27 and 61-76 are well recognized.

In order to elucidate how glycosylation influences measurements of NT-proBNP, we analyzed plasma from eight HF patients both before and after deglycosylation with two assays; one utilizing antibodies that are specific to regions with no glycosylation sites (15C4-13G12) and one in which one of the antibodies is specific to a region with glycosylation sites (11D1-13G12). Figure 11 shows that deglycosylation has a dramatic effect on the latter assay.

The glycosylation and its effect on the detection of NT-proBNP should be taken into account during assay development. We recommend selecting antibodies that are less sensitive to glycosylation.

![Figure 11](image1.png)

**Figure 11. Glycosylation affects the detection of NT-proBNP to a varying degree depending on the assay antibodies.**

Plasma samples from eight HF patients were analyzed with two different sandwich immunoassays both before and after deglycosylation. The 15C4-13G12 immunoassay (A) gave almost the same result for glycosylated (green) and deglycosylated (blue) NT-proBNP. In contrast, the MAb pair 11D1-13G12 was highly susceptible to glycosylation and could only detect the deglycosylated NT-proBNP.

![Figure 12](image2.png)

**Figure 12. Schematic presentation of NT-proBNP molecule with identified glycosylation sites (green diamonds) and anti-NT-proBNP MABs with their epitopes.**
NT-proBNP sandwich immunoassays

At HyTest, we provide several MAbs that are specific to many different epitopes along the human NT-proBNP molecule (see Figure 12). Please note that the majority of the immunoassays that detect NT-proBNP also detect the unprocessed proBNP to some extent. We have thoroughly tested all of our NT-proBNP antibodies in sandwich immunoassays as capture and detection antibodies with blood samples from HF patients, as well as using our recombinant non-glycosylated NT-proBNP and proBNP as antigens. Based on our studies we recommend selecting antibodies that are specific to the epitopes outside the central, glycosylated region (see Table 2). These MAb pairs were able to detect both the endogenous and recombinant antigens with the same efficiency. In contrast, MAb pairs that utilized at least one MAb specific to the very N-terminal part of the analyte (a.a.r. 1-12) only detected the recombinant antigens. This was presumably due to the truncation of the endogenous NT-proBNP in samples. Immunoassays with MAb pairs utilizing an antibody specific to the central region of the analyte (a.a.r. 28-56) behaved the same way. The reason for this was because the epitopes were masked by glycans and therefore scarcely accessible to antibody binding.

Table 2. Recommended MAb pairs for NT-proBNP sandwich immunoassays.

<table>
<thead>
<tr>
<th>Capture</th>
<th>Detection</th>
</tr>
</thead>
<tbody>
<tr>
<td>15C4cc</td>
<td>13G12cc</td>
</tr>
<tr>
<td>15C4cc</td>
<td>29D12cc</td>
</tr>
<tr>
<td>15F11cc</td>
<td>24E11cc</td>
</tr>
<tr>
<td>15C4cc</td>
<td>18H5cc</td>
</tr>
<tr>
<td>29D12cc</td>
<td>NT34cc</td>
</tr>
</tbody>
</table>

As the antibody performance may differ depending on the assay conditions and platform, we recommend trying all two-site MAbs combinations listed in Table 2 with a view to finding the best pair.

As a standard for NT-proBNP immunoassays we recommend using the recombinant non-glycosylated NT-proBNP (Cat.# 8NT2, see page 12). Antibodies that are specific to different regions of NT-proBNP recognize the non-glycosylated NT-proBNP expressed in E.coli with the same efficiency.

Calibration curves. All assays that utilize the recommended MAb combinations demonstrate high sensitivity (10–15 pg/ml), good kinetics and linearity. A representative calibration curve for the assay 15C4-13G12 is shown in Figure 13. For more information regarding this assay see Reference 17.

Figure 13. Calibration curve for the NT-proBNP 15C4-13G12 assay. The capture antibody 15C4 was biotinylated and the detection antibody 13G12 was labelled with Eu³⁺. Human recombinant non-glycosylated NT-proBNP (Cat.# 8NT2) was used as the antigen. A mixture of antibodies (50 μl each) and antigen (50 μl) was incubated for 30 minutes at room temperature in streptavidin-coated plates.

HyTest’s NT-proBNP assay prototypes exhibit the same clinical value as the Roche NT-proBNP assay. The NT-proBNP concentrations were measured in EDTA-plasma samples from 51 patients who were diagnosed with HF and from 53 healthy individuals (age-matched) with the Roche Cobas® e411 analyzer and our in-house sandwich immunoassays 15C4-13G12 and 29D12-NT34. The diagnostic accuracies were compared using a ROC curve analysis. Our NT-proBNP assays are based on MAbs that are specific to the glycan-free regions of NT-proBNP whereas in the Roche assay one MAb is specific to the partially glycosylated region of NT-proBNP (epitope 42-46 a.a.r.). The Roche assay is known to detect only a subfraction of endogenous NT-proBNP as the assay is sensitive to glycosylation (23-25). The ROC-AUC for the Roche assay was 0.965 (sensitivity 0.86, specificity 0.98), 0.950 (sensitivity 0.84, specificity 0.98) for the 15C4-13G12 assay and 0.951 (sensitivity 0.86, specificity 0.93) for the 29D12-NT34 assay. So, the HyTest prototype assays were comparable to the Roche assay in regard to the clinical value (Figure 14).

Figure 14. ROC curves of NT-proBNP diagnostic accuracy in heart failure. Assessed with the Roche Cobas e411 assay and HyTest 15C4-13G12 assay (left) or HyTest 29D12-NT34 assay (right).
Stability of the endogenous NT-proBNP in clinical samples. We analyzed the stability of NT-proBNP in serum samples from HF patients using the 15C4-13G12 immunoassay, in which both antibodies are specific to the stable part of the molecule (epitopes 63-71 a.a.r. and 13-20 a.a.r. respectively). More than 90% of the initial immunological activity was detected after 72 hours of incubation at +4°C and approximately 85-90% following incubation of the pooled serum for 24 hours at room temperature (see Figure 15). This indicates that if the immunoassay is designed with antibodies that recognize the stable parts of the molecule, it enables a reliable quantitation of the analyte from samples that have been stored at +4°C or even at room temperature for relatively long periods of time.

ProBNP assay development

Both we and others have shown that in addition to NT-proBNP and BNP, their precursor proBNP1-108 is also found in significant amounts in the blood samples derived from HF patients (17, 26-27). The calculated pI of proBNP is 10.12 and molecular weight is 11.9 kDa. However, its apparent molecular weight is higher due to O-linked glycosylation (27).

The majority of the existing commercial BNP and NT-proBNP assays cross-react with proBNP to varying degrees. Such cross-reactivity might skew the correlation of BNP and NT-proBNP closer to proBNP.

The level of proBNP in blood has been shown to have a high degree of correlation with both BNP and NT-proBNP, and to allow the identification of HF patients with a high risk of cardiovascular death over a long term follow-up period (28). In another study it was shown that circulating proBNP levels were associated with an increased risk of adverse cardiovascular outcomes that were independent from BNP (29).

Assays that only detect proBNP1-108 might have an enhanced analytical specificity in comparison to the commercially available assays for the measurement of BNP and NT-proBNP.

ProBNP sandwich immunoassays

We have designed prototype proBNP immunoassays that utilize one antibody which is specific to an epitope on the BNP part of the molecule and one antibody that is specific to the NT-proBNP part. A schematic presentation of the suggested epitopes is shown in Figure 16 and the recommended MAb pairs are set out in Table 3.

<table>
<thead>
<tr>
<th>Capture</th>
<th>Detection</th>
</tr>
</thead>
<tbody>
<tr>
<td>50E1</td>
<td>16F3</td>
</tr>
<tr>
<td>50E1</td>
<td>18H5</td>
</tr>
</tbody>
</table>

Table 3. Recommended MAb pairs for proBNP sandwich immunoassays.

Figure 15. Stability of endogenous NT-proBNP when measured with the 15C4-13G12 sandwich immunoassay. Pooled serum from patients with HF was incubated at +4°C (blue) and at room temperature (red) for 72 hours.

Figure 16. Epitope locations of MAbs that are recommended for the development of proBNP sandwich immunoassays.

These pairs demonstrate high sensitivity, good kinetics and recognize recombinant glycosylated and non-glycosylated proBNP as well as proBNP in the blood of HF patients.

Calibration curves. The analytical sensitivity of the assay 50E1-16F3 using a recombinant non-glycosylated proBNP (Cat.# 8PRO9) as the calibrator is better than 3 pg/ml (see Figure 17).

Figure 17. Calibration curve for the proBNP 50E1-16F3 sandwich immunoassay. The capture antibody 50E1 was biotinylated and the detection antibody 16F3 was labelled with Eu³⁺. Recombinant non-glycosylated proBNP (Cat.# 8PRO9) was used as the antigen. A mixture of antibodies (50 μl each) and antigen (50 μl) was incubated for 30 minutes at room temperature in streptavidin-coated plates.
Recombinant proteins

Recombinant glycosylated human proBNP

We provide recombinant proBNP expressed in a mammalian cell line (Cat.# 8GBP3). This protein is glycosylated and migrates in SDS-PAGE as a diffuse band with an apparent molecular mass of approximately 30 kDa (see Figure 18). We recommend using the glycosylated proBNP as a standard for BNP and proBNP immunoassays.

Figure 18. SDS-PAGE of recombinant glycosylated proBNP (Cat.# 8GBP3) in reducing conditions.

Glycosylated proBNP as a stable standard for BNP immunoassays. Plasma BNP concentrations measured by various commercial immunoassays differ substantially, which complicates the interpretation of the results. In addition to the different epitope specificities of the antibodies utilized in these assays, one factor that might contribute to these discrepancies could be the absence of a common calibrator.

In several BNP assays, synthetic BNP is currently used as a calibrator. However, a substantial part of the BNP immunoreactivity in clinical samples comes from glycosylated proBNP, which, however, is not equally recognized by different assays. On the other hand, the synthetic BNP is also relatively unstable when reconstituted in plasma and this limits its use as a calibrator in BNP immunoassays.

The advantage of recombinant glycosylated proBNP is its similarity to endogenous proBNP in terms of the presence of O-linked glycans as well as its better stability as compared to synthetic BNP. Figure 19 shows a comparison of stabilities of synthetic BNP, recombinant glycosylated proBNP and endogenous proBNP (a plasma sample from an HF patient) measured with two representative BNP immunoassays. The recombinant glycosylated proBNP retained 90-96% of its immunoreactivity after 24 hours at room temperature, whereas the apparent stability of synthetic BNP was significantly lower.

Figure 19. Stability of synthetic BNP vs. endogenous and recombinant glycosylated proBNP. Endogenous proBNP (plasma from HF patients - blue), recombinant glycosylated proBNP (green) and synthetic BNP (red) were reconstituted in pooled normal human EDTA-plasma and incubated at room temperature for different time periods. Immunological activity was measured with two BNP immunoassays: 50E1-24CS (A) and 57H3-429 (B).
Human recombinant (non-glycosylated) proBNP expressed in *E. coli*

Human recombinant proBNP (Cat.# 8PRO9; a.a.r. 1-108) is expressed in *Escherichia coli*. The polypeptide has the same sequence as the endogenous protein except for an additional Met residue at its N-terminus. The antigen is recognized by BNP-specific monoclonal antibodies (Cat. # 4BNP2) as well as by all NT-proBNP specific MAbs (Cat.# 4NT1). ProBNP is highly purified, with purity exceeding 95% according to Tricine-SDS-PAGE (see Figure 20) and HPLC studies. The antigen could be used as either a calibrator or standard in BNP, NT-proBNP and proBNP immunoassays. The calibration curves with the non-glycosylated proBNP as the antigen are provided in Figure 5 for two conventional BNP immunoassays; in Figure 8 for the SES-BNP assay and in Figure 17 for a proBNP immunoassay.

Recombinant non-glycosylated NT-proBNP

Human recombinant NT-proBNP (Cat.# 8NT2; a.a.r. 1-76) is expressed in *Escherichia coli*. The polypeptide has the same sequence as the endogenous NT-proBNP except for an additional Met residue at the N-terminus. The antigen is recognized by MAbs that are specific to different parts of NT-proBNP (Cat. # 4NT1).

The purity of NT-proBNP exceeds 95% according to Tricine-SDS-PAGE (see Figure 20) and HPLC studies. The antigen could be used as either a calibrator or standard in an NT-proBNP assay. The calibration curve with the recombinant NT-proBNP as the antigen is provided in Figure 13 for an NT-proBNP assay.

![Figure 20. Tricine-SDS-PAGE in reducing conditions of rec. non-glycosylated proBNP (Cat.# 8PRO9) and NT-proBNP (Cat.# 8NT2). 3 μg of each protein was loaded into wells.](image)
References

Selected proBNP related articles from HyTest scientists


In this study we describe the development of monoclonal antibodies that are specific to proBNP, NT-proBNP and BNP. Using carefully characterized immunoassays that are based on these antibodies as well as the Beckman Access BNP assay, we show that proBNP is the major antigen that contributes to BNP immunological activity in the blood of HF patients. We also demonstrate that the ratio of proBNP to BNP is significantly higher than previously thought.


In this study we investigate how glycosylation affects the ability of NT-proBNP specific MAbs to recognize the molecule and demonstrate that O-linked glycosylation renders the central region of NT-proBNP scarcely accessible to antibody binding. This also applies to the Roche Elecsys 2010 NT-proBNP assay which utilizes polyclonal antibodies that are specific to epitopes partially covered by glycans, although the effect with the Roche assay is smaller. In addition, we show that the effect of glycosylation to detection by antibodies varies between patient samples, which indicates that the glycosylation pattern of NT-proBNP in samples is not identical and this can lead to unpredictable errors in measurements. Finally, we show that antibodies which are specific to N-terminal and C-terminal regions of NT-proBNP are less influenced by glycosylation and should therefore be considered when designing a quantitative NT-proBNP immunoassay.


In this article we describe the development of a novel type of sandwich BNP assay that requires only one epitope on the BNP molecule for antigen immunodetection. This Single Epitope Sandwich BNP assay (SES-BNP™) enables improved apparent stability of the BNP in clinical samples as it is less influenced by the proteolytic degradation of BNP from its N-termini and C-termini.


In this study we show that the processing of proBNP into NT-proBNP and BNP depends on the glycosylation of threonine residue at position 71 (Thr71) of proBNP. By investigating the immunoreactivity of endogenous NT-proBNP and proBNP in the plasma of HF patients through the use of a panel of MAbs that are specific to different regions of the molecules, deglycosylation assays as well as alanine-scanning mutagenesis, we demonstrate that an O-linked glycan at Thr71 suppresses the cleavage of proBNP, whereas proBNP with Thr71 without a glycan is readily cleaved by proprotein convertase(s).


In this article, we provide new information on proBNP processing mechanisms. Our data suggests the involvement of furin, and to a lesser extent corin, in the processing of proBNP into NT-proBNP and BNP. We show for the first time that a portion of endogenous proBNP in the plasma of HF patients lacks an attached glycan at Thr71 residue which normally makes proBNP susceptible to cleavage by convertase(s) into NT-proBNP and BNP. These findings improve our understanding of the different circulating forms of proBNP and its derivatives, as well as our comprehension of the cellular mechanisms of proBNP processing.


In this article we compare our SES-BNP assay to the Siemens Advia Centaur BNP Assay by analyzing the BNP concentration in 94 HF patient samples. These assays utilize antibodies that recognize different epitopes on the BNP molecule. The SES-BNP assay that is specific to only one epitope on the relatively stable ring structure sometimes measured higher BNP concentrations than the Siemens assay, which in turn uses a MAb that is specific to the C-terminal epitope 27-32. We suggest that the difference is due to the inability of the Siemens assay to detect C-terminally truncated BNP forms, which can lead to an underestimation of BNP/proBNP concentrations. This data also highlights the importance of a proper choice of the epitopes to ensure reliable BNP immunodetection.

REVIEW. The aim of this review is to summarize the available data in the field of human proBNP maturation and processing, and to discuss potential clinical implications.


In this study we injected human proBNP into rats and used different BNP, NT-proBNP and proBNP immunoassays and mass spectrometry to analyze whether it could be processed in circulation. Our results indicate that proBNP can be cleaved in circulation, resulting in the formation of active BNP, which suggests that peripheral proBNP processing might be an important regulatory step rather than mere degradation.


In this article, we study the susceptibility of BNP and proBNP to proteolysis by neprilysin in vitro. Our data firstly suggested that the major BNP immunoreactive form, proBNP, is resistant to degradation by neprilysin, and, secondly, the effect of neprilysin inhibition (e.g. by Entresto™, which is a recently approved heart failure drug containing a neprilysin inhibitor and an angiotensin II receptor inhibitor) might be assay dependent. We assume that BNP immunoassays utilizing antibodies specific to the region Arg17-Ile18 are more sensitive to the modulation of neprilysin activity than immunoassays with antibodies that do not have epitopes comprising this site, e.g. the SES-BNP assay.

Semenov AG, Katrukha AG. *Analytical Issues with Natriuretic Peptides – has this been Overly Simplified?* EJIFCC. 2016 Jul; 27(3): 189–207.

REVIEW. In this review, we summarize the recent advances in the understanding of the complexity of the natriuretic peptides system and discuss related analytical issues, which open new horizons, as well as challenges for clinical diagnostics.


In this study our researchers, in collaboration with Prof. Fred S. Apple and his team, compared six different recombinant BNP-related proteins in order to find out if any of them would reduce the between-assay variability of five commercial BNP assays. Based on the findings in this study, it was determined that one form of glycosylated proBNP could be a good candidate to serve as a common calibrator for BNP immunoassays in order to reduce the between-assay variability.

**HyTest’s patents and trademarks**

Imunoassay Kit for Quantification of BNP and proBNP (US 9,145,459).

Stable Standards for BNP Immunoassays (EP 2084544, CN 101641601, CA 2669024).

Imunoassay for Quantification of an Unstable Antigen Selected from BNP and proBNP (US 9,034,591, US 9,034,592, JP 5686593, CN 101842707, CA 268391, EP 2135087).

SES-BNP™ is a trademark or registered trademark of HyTest Ltd. All other trademarks are the property of their respective owners.

Please note that the results shown in this TechNotes have been obtained using in vivo produced monoclonal antibodies. MAbs produced in cell culture are expected to have a similar performance as the in vivo produced MAbs.
## TechNotes | Human ProBNP, BNP and NT-proBNP

### Ordering information

#### MONOCLONAL ANTIBODIES

<table>
<thead>
<tr>
<th>Product name</th>
<th>Cat. #</th>
<th>MAb</th>
<th>Subclass</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>BNP</td>
<td>4BNP2</td>
<td>24C5</td>
<td>IgG1</td>
<td>EIA, WB, a.a.r. 11-17</td>
</tr>
<tr>
<td></td>
<td></td>
<td>26E2</td>
<td>IgG1</td>
<td>EIA, WB, a.a.r. 11-22</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50E1</td>
<td>IgG1</td>
<td>EIA, WB, a.a.r. 26-32</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50B7</td>
<td>IgG2a</td>
<td>EIA, WB, a.a.r. 26-32</td>
</tr>
<tr>
<td></td>
<td></td>
<td>57H3</td>
<td>IgG2a</td>
<td>EIA, WB, a.a.r. 26-32</td>
</tr>
<tr>
<td></td>
<td>4BNP2cc</td>
<td>24C5cc</td>
<td>IgG1</td>
<td>In vitro, EIA, WB, a.a.r. 11-17</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50E1cc</td>
<td>IgG1</td>
<td>In vitro, EIA, WB, a.a.r. 26-32</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50B7cc</td>
<td>IgG2a</td>
<td>In vitro, EIA, WB, a.a.r. 26-32</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100cc</td>
<td>IgG2a</td>
<td>In vitro, EIA, a.a.r. 10-15</td>
</tr>
<tr>
<td></td>
<td></td>
<td>130cc</td>
<td>IgG1</td>
<td>In vitro, EIA, a.a.r. 15-22</td>
</tr>
<tr>
<td>Immune complex (24C5-BNP/proBNP)</td>
<td>4BFab5</td>
<td>Ab-BNP2</td>
<td>IgG2a</td>
<td>EIA (only as pair with MAb 24C5, Cat.# 4BNP2)</td>
</tr>
<tr>
<td></td>
<td>4BFab5cc</td>
<td>Ab-BNP2cc</td>
<td>IgG2a</td>
<td>In vitro, EIA (only as pair with MAb 24C5, Cat.# 4BNP2)</td>
</tr>
<tr>
<td>NT-proBNP</td>
<td>4NT1</td>
<td>5B6</td>
<td>IgG1</td>
<td>EIA, WB, a.a.r. 1-12</td>
</tr>
<tr>
<td></td>
<td></td>
<td>29D12</td>
<td>IgG2a</td>
<td>EIA, WB, a.a.r. 5-12</td>
</tr>
<tr>
<td></td>
<td></td>
<td>13G12</td>
<td>IgG2a</td>
<td>EIA, WB, a.a.r. 15-20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>18H5</td>
<td>IgG1</td>
<td>EIA, WB, a.a.r. 15-20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16F3</td>
<td>IgG1</td>
<td>EIA, WB, a.a.r. 15-20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15F11</td>
<td>IgG2b</td>
<td>EIA, WB, a.a.r. 13-24</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7B5</td>
<td>IgG1</td>
<td>EIA, WB, a.a.r. 15-21</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11D1</td>
<td>IgG1</td>
<td>EIA, WB, a.a.r. 31-39</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16E6</td>
<td>IgG1</td>
<td>EIA, WB, a.a.r. 34-39</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15D7</td>
<td>IgG1</td>
<td>EIA, WB, a.a.r. 48-56</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15C4</td>
<td>IgG2b</td>
<td>EIA, WB, a.a.r. 63-71</td>
</tr>
<tr>
<td></td>
<td></td>
<td>24E11</td>
<td>IgG2a</td>
<td>EIA, WB, a.a.r. 67-76</td>
</tr>
<tr>
<td></td>
<td></td>
<td>28F8</td>
<td>IgG2a</td>
<td>EIA, WB, a.a.r. 67-76</td>
</tr>
<tr>
<td></td>
<td>4NT1cc</td>
<td>29D12cc</td>
<td>IgG2a</td>
<td>In vitro, EIA, WB, a.a.r. 5-12</td>
</tr>
<tr>
<td></td>
<td></td>
<td>13G12cc</td>
<td>IgG2a</td>
<td>In vitro, EIA, WB, a.a.r. 15-20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>18H5cc</td>
<td>IgG1</td>
<td>In vitro, EIA, WB, a.a.r. 15-20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15F11cc</td>
<td>IgG2b</td>
<td>In vitro, EIA, WB, a.a.r. 13-24</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15C4cc</td>
<td>IgG2b</td>
<td>In vitro, EIA, WB, a.a.r. 63-71</td>
</tr>
<tr>
<td></td>
<td></td>
<td>24E11cc</td>
<td>IgG2a</td>
<td>In vitro, EIA, WB, a.a.r. 67-76</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NT34cc</td>
<td>IgG1</td>
<td>In vitro, EIA, WB, a.a.r. 25-34</td>
</tr>
</tbody>
</table>

#### ANTIGENS

<table>
<thead>
<tr>
<th>Product name</th>
<th>Cat. #</th>
<th>Purity</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>NT-proBNP, recombinant</td>
<td>8NT2</td>
<td>&gt;95%</td>
<td>Recombinant</td>
</tr>
<tr>
<td>ProBNP, recombinant</td>
<td>8PRO9</td>
<td>&gt;95%</td>
<td>Recombinant</td>
</tr>
<tr>
<td>ProBNP, glycosylated, recombinant</td>
<td>8GBP3</td>
<td>&gt;95%</td>
<td>Recombinant</td>
</tr>
</tbody>
</table>

#### DEPLETED PLASMA

<table>
<thead>
<tr>
<th>Product name</th>
<th>Cat. #</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>BNP and NT-proBNP free plasma</td>
<td>8BFP</td>
<td>Pooled normal human plasma</td>
</tr>
</tbody>
</table>